Clinical trial
Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes
NCT00191282 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191282 |
|---|---|
| Title | Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes |
| Official title | Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes (HEART2D) |
| Acronym | IONM |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2, Acute Myocardial Infarction |
| Intervention type | Drug |
| Interventions | Insulin lispro, Human insulin isophane suspension (NPH), Insulin glargine, Human insulin isophane suspension, Human insulin 30/70 |
| Enrollment | 1,116 |
| Start date | Oct 1, 2002 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Jan 20, 2011 |
| Countries | Canada, Croatia, Czechia, Germany, Hungary, India, Israel, Lebanon, Poland, Romania, Russia, Slovakia and 5 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: